COR Stock Recent News
COR LATEST HEADLINES
COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Cencora (COR) reported earnings 30 days ago. What's next for the stock?
The GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount. SFM, COR and AXP are some stocks that hold promise.
Cencora (COR) possesses solid growth attributes, which could help it handily outperform the market.
Cencora offers steady revenue growth from pharmaceutical distribution, benefiting from rising healthcare demand and an aging population. The company has a strong economic moat, low leverage, BBB+ credit rating, and an active share repurchase program, enhancing shareholder returns. Strategic acquisitions like Retina Consultants of America position Cencora for long-term success, with management guiding for 10% annual EPS growth.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. AXP, COR and TPX hold promise.
Walgreens Boots Alliance has sold more shares of drug distributor Cencora for proceeds of about $300 million, “primarily for debt paydown and general corporate purposes,” the company said Thursday night.
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of approximately $50 million in concurrence with Walgreens Boots Alliance's sale of Cencora shares pursuant to Rule 144 under the Securities Act of 1933, as amended. Cencora intends to repurchase shares from Walgreens Boots Alliance at the price per share equal to the price in the Rule 144 sale. The con.